GREAT NEWS! Noventure is delighted to announce that our medical device Tasectan has just been granted a new CЄ Certificate under MDR Regulation. With 3,7 Mio packs, equivalent to more than 51 Mio of standard units sold through our licensees in 34 countries during 2023, the Tasectan franchise is already [...]
The newer antidiarrheal agents include the mucoprotectants gelatin tannate and xyloglucan. Both were able to attenuate cholera toxin-induced intra-loop water secretion in an experimental study in rats. This supports previous evidence that their mechanism of mucosal protection is closely related to their chemical structures, and involves the ability to form [...]
Noventure is proud to announce the launch of XILAPLUS® in Estonia, Latvia and Lithuania by our partner company Miecys XILAPLUS® is specifically formulated for the control and reduction of diarrheal events of various etiologies in adults, children, and infants. XILAPLUS® is a class III medical device and complies with the [...]
Santos J. et al. Randomized, placebo-controlled trial of xyloglucan and gelose for the treatment of acute diarrhea in children.Expert Rev Gastroenterol Hepatol: 2020 Oct 19;1-7. doi: 10.1080/17474124.2021.1833715. Santos J. et al. Randomized, placebo-controlled trial of xyloglucan and gelose for the treatment of acute diarrhea in children.Expert Rev Gastroenterol Hepatol: 2020 Oct 19;1-7. doi: 10.1080/17474124.2021.1833715. [...]
Elena D Serban & Mihai Manolache; Journal of Comparative Effectiveness ResearchVol. 8, No. 3 Journal of Comparative Effectiveness ResearchVol. 8, No. 3 Publication of a retrospective, observational study on Gelatin tannate versus other antidiarrheal medication in children with acute gastroenteritis. Aim: To evaluate the effectiveness and safety of gelatin tannate [...]
Gelsectan®, Noventure´s new medical device intended for IBS-D, was presented at Noventure´s stand during the 3rd Meeting of the Federation of Neurogastroenterology and Motility, from 29 August to 1 September 2018 in Amsterdam, The Netherlands. An observational study showing significant symptoms´ improvement in patients with IBS-D treated with Gelsectan® in [...]
HeleneEutamene, FannyPlacide, ValerieTondereau, VassiliaTheodorou https://doi.org/10.1016/S0016-5085(18)33080-4 BACKGROUND: Irritable Bowel Syndrome (IBS) is a common disorder characterized by visceral hypersensitivity and increased intestinal permeability. Stressful events can affect the onset and course of IBS. In rats, stress also induces visceral hypersensitivity and gut hyperpermeability. Mucoprotectant agents such as gelatin tannate and xyloglucan, [...]
Octavian Alexea, Vlad Bacarea and Nuria Pique. United European Gastroenterol J. 2016 Jun;4(3):455-65. Background: A medical device containing the film-forming agent reticulated protein and a prebiotic mixture of vegetable oligo- and polysaccharides has been developed, recently receiving European approval as MED class III for the treatment of chronic/functional or recidivant [...]
Maurizio Mennini1,Carlo Tolone, Antonella Frassanito, Fabio Midulla3, Salvatore Cucchiare, Marina Aloi. Paediatr Drugs. 2016 Dec 20. doi: 10.1007/s40272-016-0207-z Background: Oral rehydration therapy is the recommended treatment for acute childhood gastroenteritis. The aim of this study was to assess the efficacy and safety of gelatin tannate plus oral rehydration compared with [...]
Noventure is glad to announce the launch of TASECTAN® AF in Denmark by its partner company Pharmaforce, thus setting a record time-to-market, after Noventure granted Pharmaforce exclusive distribution right for Tasectan® AF in the Nordic markets last April. Tasectan® AF is intended to restore the physiological functions of the intestinal [...]